The AUM LifeTech , Inc. on the event will present the preclinical developments on fatal diseases namely HIV, Parkinson’s Disease, and Lung Cancer. The biotechnology company reveals the information. In the announcement, the company confirmed that it had been chosen by the National Institutes of Health (NIH) to demonstrate the preclinical developments.
The company has developed a self-performing non-viral technology that may target the RNA for the medical development in contagious diseases, oncology, and CNS. AUM LifeTech Founder and Chief Executive Officer, Veenu Aishwarya will present their company’s update on their preclinical data.The biotechnology company has developed a preclinical program in cancer immunotherapy.
All the information regarding the gene silencing technology, insight into therapeutic developments, and the preclinical study will be made available for the people attending the event. Before the live event starts, the attendees can see the presentation. Expressing about the company’s selection by NIH for the event, Veenu Aishwarya said they are excited about their preclinical data as they move towards the new growth stages.